AU2017294572B2 - 4-anilino-quinoline compounds as anti-cancer agents - Google Patents

4-anilino-quinoline compounds as anti-cancer agents Download PDF

Info

Publication number
AU2017294572B2
AU2017294572B2 AU2017294572A AU2017294572A AU2017294572B2 AU 2017294572 B2 AU2017294572 B2 AU 2017294572B2 AU 2017294572 A AU2017294572 A AU 2017294572A AU 2017294572 A AU2017294572 A AU 2017294572A AU 2017294572 B2 AU2017294572 B2 AU 2017294572B2
Authority
AU
Australia
Prior art keywords
amine
quinolin
methoxyphenyl
chloro
diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017294572A
Other languages
English (en)
Other versions
AU2017294572A2 (en
AU2017294572A1 (en
Inventor
Rachid BENHIDA
Pascal DAO
Donatis Gian Marco De
Anthony Martin
Thierry Passeron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Nice Sophia Antipolis UNSA, Centre Hospitalier Universitaire de Nice filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2017294572A1 publication Critical patent/AU2017294572A1/en
Publication of AU2017294572A2 publication Critical patent/AU2017294572A2/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, INSERM (Institut National de la Santé et de la Recherche Médicale), CHU DE NICE, Université Côte d’Azur reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - Request for Assignment Assignors: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, CHU DE NICE, INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Nice Sophia Antipolis
Application granted granted Critical
Publication of AU2017294572B2 publication Critical patent/AU2017294572B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017294572A 2016-07-08 2017-07-10 4-anilino-quinoline compounds as anti-cancer agents Active AU2017294572B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305862 2016-07-08
EP16305862.1 2016-07-08
PCT/EP2017/067306 WO2018007648A1 (en) 2016-07-08 2017-07-10 4-anilino-quinoline compounds as anti-cancer agents

Publications (3)

Publication Number Publication Date
AU2017294572A1 AU2017294572A1 (en) 2019-01-24
AU2017294572A2 AU2017294572A2 (en) 2019-05-09
AU2017294572B2 true AU2017294572B2 (en) 2021-11-04

Family

ID=56413606

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017294572A Active AU2017294572B2 (en) 2016-07-08 2017-07-10 4-anilino-quinoline compounds as anti-cancer agents

Country Status (6)

Country Link
US (1) US20200181089A1 (enExample)
EP (1) EP3481806B1 (enExample)
JP (1) JP7039579B2 (enExample)
AU (1) AU2017294572B2 (enExample)
CA (1) CA3029889A1 (enExample)
WO (1) WO2018007648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134975A1 (en) 2018-01-05 2019-07-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivatives, method of preparation and applications thereof
CN113549018B (zh) * 2020-04-24 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
EP4169904A1 (en) 2021-10-25 2023-04-26 Yukin Therapeutics Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075981A (en) * 1958-04-03 1963-01-29 Sterling Drug Inc 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation
CN102249997A (zh) * 2011-05-25 2011-11-23 沈阳化工大学 一组具有抗肿瘤活性的4-取代苯氨基喹啉化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
CN103232444B (zh) 2013-04-18 2015-07-22 中国人民解放军军事医学科学院微生物流行病研究所 萘酚喹衍生物及其制备和其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075981A (en) * 1958-04-03 1963-01-29 Sterling Drug Inc 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation
CN102249997A (zh) * 2011-05-25 2011-11-23 沈阳化工大学 一组具有抗肿瘤活性的4-取代苯氨基喹啉化合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEAUCHARD A ET AL, "Synthesis of original thiazoloindolo[3,2-c]quinoline and novel 8-N-substituted-11H-indolo[3,2-c]quinoline derivatives from benzotriazoles. Part I", TETRAHEDRON, vol. 62, no. 8, pages 1895 - 1903, (2006-02-20) *
CAROLINE MEYERS ET AL, "Auto-Tandem Catalysis: Synthesis of Substituted 11H-Indolo[3,2-c]quinolinesvia ...", ADVANCED SYNTHESIS & CATALYSIS, DE, (2008-02-22), vol. 350, no. 3, pages 465 - 470 *
DAKSHANAMURTHY SIVANESAN ET AL, "In-silico fragment-based identification of novel angiogenesis inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2007-07-15), vol. 17, no. 16, pages 4551 - 4556 *
Dan Liu, "Molecules Free Full-Text Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline Derivatives", molecules, (2015-12-23), pages 1 - 8, URL: http://www.mdpi.com/1420-3049/21/1/21, (2016-08-30) *
Elaine S Coimbra ET AL, "Amodiaquine analogs. Synthesis and anti-leishmanial activity", Mediterranean Journal of Chemistry, (2011-01-01), pages 106 - 113, URL: http://www.medjchem.com/images/stories/V1N3/mjcsouza2.pdf *
GOZALBES RAFAEL ET AL, "Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, (2013-01-31), vol. 21, no. 7, pages 1944 - 1951 *
HE L ET AL, "Design of antineoplastic agents based on the '2-phenylnaphthalene type' structural ... ", EUROPEAN JOURNAL OF MEDICINAL CHEMI, (2003-01-01), vol. 38, no. 1, pages 101 - 107 *
ROSARIO SÁNCHEZ-MARTÍN ET AL, "Symmetrical Bis-Quinolinium Compounds: New Human Choline Kinase Inhibitors with Antiproliferative Activity against the HT-29 Cell Line", JOURNAL OF MEDICINAL CHEMISTRY, 2005 vol. 48 no. 9, pages 3354 - 336 *

Also Published As

Publication number Publication date
CA3029889A1 (en) 2018-01-11
US20200181089A1 (en) 2020-06-11
AU2017294572A2 (en) 2019-05-09
AU2017294572A1 (en) 2019-01-24
EP3481806C0 (en) 2023-06-07
EP3481806A1 (en) 2019-05-15
JP7039579B2 (ja) 2022-03-22
EP3481806B1 (en) 2023-06-07
JP2019521193A (ja) 2019-07-25
WO2018007648A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
EP3080134B1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
JP2024522293A (ja) ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
WO2022105855A1 (en) Kras g12d inhibitors
CA2889389C (en) Benzene sulfonamide thiazole compounds
PH12014501626B1 (en) Therapeutically active compounds and their methods of use
US20210292340A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
CN105722840B (zh) 作为PI3K、mTOR抑制剂的稠合喹啉化合物
EP3917926B1 (en) Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
CN118005656A (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
AU2017294572B2 (en) 4-anilino-quinoline compounds as anti-cancer agents
EP3060562B1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
AU2019205595B2 (en) Substituted halo-quinoline derivatives, method of preparation and applications thereof
CN116057042B (zh) 丙烯酰胺取代的茚满化合物及其治疗用途
MX2008013435A (es) Sintesis y usos de derivados de acido piroglutamico.
JP7152078B2 (ja) ホウ酸塩ベースの薬物およびその使用
CN115304600A (zh) mTOR抑制剂、制备方法及用途
CN120398958A (zh) 作为帽依赖性内切核酸酶抑制的化合物及其应用
HK40006287A (en) Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels
HK1228914A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
HK1228914B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
JPWO2001007031A1 (ja) ベンゼン誘導体およびそれを含有する免疫賦活性組成物または薬剤感受性回復剤
HK1226395B (en) Substituted pyrimidine compounds and their use as syk inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 APR 2019

PC1 Assignment before grant (sect. 113)

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Free format text: FORMER APPLICANT(S): UNIVERSITE DE NICE SOPHIA ANTIPOLIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CHU DE NICE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: CHU DE NICE

Free format text: FORMER APPLICANT(S): UNIVERSITE DE NICE SOPHIA ANTIPOLIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CHU DE NICE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: UNIVERSITE COTE D'AZUR

Free format text: FORMER APPLICANT(S): UNIVERSITE DE NICE SOPHIA ANTIPOLIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CHU DE NICE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER APPLICANT(S): UNIVERSITE DE NICE SOPHIA ANTIPOLIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); CHU DE NICE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

FGA Letters patent sealed or granted (standard patent)